Kornimate/medical-research-clean huggingface dataset:
epidemiological analysis of ambulant patients in a covid-19 outpatient clinic

Conditions: COVID-19

Summary: there is insufficient knowledge about transmission routes and the effectiveness of general protective measures to prevent infection, such as the closure of schools or the wearing of mouthguards. this will be illustrated using the example of the covid-19 outpatient clinic in solingen and the positive covid-19 tests registered there. another aspect we would like to address in this study is the number of covid-19 tests performed against the background of political events or dramatic accumulations of covid-19 cases in other parts of germany or europe. do speeches by political leaders about the covid-19 situation or a very strong regional spread of infection elsewhere have an impact on the frequency with which people react sensitively to suspicious symptoms and undergo testing for infection?

the aim of this study is to analyse the frequency of positive covid-19 tests and the infection chains in solingen since february 2020: 1. a prospective survey (telephone contact) of the positively tested patients is done to analyze the social environment and thus provide information about possible transmission routes. is transmission mainly within the family through visits from relatives or rather through large extra-familial gatherings, such as in the case of the open huts and après-ski bars in ischgl? are there age- or gender-specific transmission routes (personal habits, travel)? 2. analysis of the number of positive tests in connection with general measures to contain the infection (closure of schools, mouthguards obligation, etc.) 3. characterization of positively tested patients based on anthropometric data and medical history. 4. the effect of political events and developments in world affairs on the daily visitor frequency in the covid-19 outpatient clinic will be retrospectively investigated. is there an accumulation of tests after speeches by politicians or public figures (angela merkel, armin laschet, queen elizabeth ii, etc.) or after dramatic infection numbers in other parts of germany or europe (heinsberg, ischgl, etc.)?

Eligibility criteria:
inclusion criteria: * positive covid-19 test result exclusion criteria: * negative covid-19 test result * any medical, psychological or other condition which restricts the ability to provide information or consent of the patient for voluntary participation in this examination
articaine and bupivacaine in impacted tooth surgery

Conditions: Impacted Third Molar Tooth

Summary: articaine is a common local anesthetic used in oral surgery and belongs to the amide group of it has fast onset with little side effects. bupivacaine is preferred in prolonged surgical procedures with its long duration of action and residual analgesic effect. the aim of this study was to evaluate the anesthetic, analgesic, hemodynamic effects of 4% articaine and 0.5% bupivacaine in extraction of impacted mandibular third molar teeth in intraoperative and postoperative periods. hemodynamic parameters, onset of anesthetic action, total amount, intraoperative comfort, intraoperative bleeding, duration of postoperative anesthesia and analgesia, rescue analgesic use, maximum incisal opening and postoperative pain at 6th, 12th, 24th, 48th and 72th hours and 7th day using a visual analogue scale be evaluated.


Eligibility criteria:
inclusion criteria: * patients above 18 years of age with bilaterally symmetric, impacted or partially impacted mandibular third molar and patients classified in american society of anesthesiologists (asa) 1 group. exclusion criteria: * patients with the presence of any systemic diseases, patients allergic to articaine and bupivacaine or any other nsaids and patients with analgesic or anti-inflammatory drugs usage in 15 days before to the surgery.
self-control trial to evaluate the remission rate in newly diagnosed type 2 diabetes patients after treatment with insulin aspart

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in asia. the aim of this trial is evaluate the remission rate in newly diagnosed subjects with type 2 diabetes after short-term intensive treatment with insulin aspart and insulin nph.


Eligibility criteria:
inclusion criteria: * type 2 diabetes newly diagnosed within 6-12 months * fbg: 11.1-17.0 mmol/l * body mass index (bmi) larger than 25.0 kg/m2 exclusion criteria: * known or suspected allergy to trial product(s) or related products * recurrent major hypoglycaemia as judged by the investigator
faster identification of tb and evaluation of drug resistance in hiv-infected people

Conditions: HIV Infections

Summary: early identification of tuberculosis (tb) is of particular importance in hiv-infected individuals, as a delay of therapy can be devastating in those with compromised immune systems. diagnosis of tb in hiv is difficult, however, because 24-61% of hiv co-infected individuals with pulmonary tb have negative tb test results. in addition, conventional testing can take 6 weeks or longer and may not be available at all in many settings. this study is being conducted to see whether some new tests for identifying tb and for identifying resistance to tb drugs are at least as accurate as the current testing methods when used on hiv-infected individuals. the study will also assess whether the new tests can provide accurate results faster than the current methods.

early diagnosis of tuberculosis (tb) is of particular importance in hiv-infected individuals, as a delay of therapy can be devastating in those with compromised immune systems. diagnosis of tb in hiv can be a particular challenge, however, because 24-61% of hiv co-infected individuals with pulmonary tb are smear-negative. conventional solid media-based culture can take 6 weeks or longer for mycobacterial growth, and may not be available at all in many settings. the purpose of this study is to determine whether new tests for identifying tb and resistance to tb drugs are as effective as current tests and if these new tests can provide accurate results faster than the current method of testing for tb and drug resistance. this trial will enroll hiv-infected individuals who are suspected to be co-infected with tb. participants may be in this trial for up to nine months, depending on their test results. during the study, participants will provide one or two sputum samples, have a chest x-ray, and may have blood collected.

Eligibility criteria:
inclusion criteria: * hiv-1 infection, as documented at any time prior to study entry by a rapid hiv test or any licensed elisa test kit * probable or confirmed pulmonary tb at the time of enrollment * current use of an anti-tb regimen for treatment of active tb for fewer than 7 days prior to sputum sample collection or anticipated initiation of same within 30 days after study entry * ability and willingness of participant or legal guardian/representative to provide informed consent. exclusion criteria * receipt of 7 or more cumulative days of anti-tb treatment within 12 months prior to sputum collection * inability to provide sputum sample
effect of immersive virtual reality on pain in different dental procedures in children

Conditions: Fissure Sealant; Space Maintainer; Impression Taking for Space Maintainers; FLUORIDE THERAPY; SCALING; Stainless-steel Crown; Pulp Therapy; Restorations; TOOTH Extraction

Summary: the current study aims to assess virtual reality as an effective pain management technique for children undergoing different dental procedures. the iwear is the immersive virtual reality device was used for this study from (vuzix®, rochester, new york, usa). the iwear consists of a lightweight high-end pair of video headphones that contain pair of vr goggles

the peadiatric dentist examined children to assess their needs. at the screening, a full mouth oral examination was performed. different dental procedures needed were determined based on the outcome of the clinical examination performed. some of these dental procedures did not require administration of local anesthesia (la), such as fissure sealant, space maintainer, fluoride therapy, impression taking for space maintainers, and scaling. other dental procedures require the administration of la , such as stainless-steel crown, pulp therapy, restorations, and extraction (figure 2). the peadiatric dentist divided the children into two groups (group a \& b) according to the need for usage of la. the children with dental procedures not requiring administration of la were assigned to group a, and the children with dental procedures requiring administration of la were assigned to group b. a computer-generated random number was used to randomly divide the children in group a into two sub-groups(group a1 \& a2) according to the usage of vr. patients included in group a1 randomly assigned to receive no vr. on the other hand, patients included in group a2 randomly assigned to receive vr. also, children in group b were randomly assigned into two sub-groups (group b1 \& b2) to receive no vr or vr respectively.

Eligibility criteria:
inclusion criteria: * children aged 5-12 years * good general health, * taking no medications, * willingness to participate in the study exclusion criteria: * subjects with a convulsive disorder, * subjects with a history of serious vestibular abnormalities, * subjects with musculoskeletal disorders, or developmental delay taking psychotropic drugs

Keywords: virtual reality pain dental
body image after head and neck cancer treatment

Conditions: Head and Neck Cancer

Summary: this is a pilot study of the body image after head and neck cancer treatment program \[bihnc\]. it is a six-week, psychoeducational, web-based program that includes e-learning didactic modules and personal reflection activities for participants to complete.

specific aim 1: to assess the feasibility and acceptability of \[bihnc\] in patients who have completed treatment for head and neck cancer and who have body image concerns. h1a: eighty percent of enrolled study participants who complete baseline self-report measures will complete the bihnc program. h1b: eighty percent of study participants completing the bihnc program will rate it acceptable on the intervention evaluation form. specific aim 2: to assess the preliminary efficacy of bihnc for reducing body image concerns in patients who have completed treatment for head and neck cancer and who have body image concerns. h2: body image scores will improve from pre- to post- intervention

Eligibility criteria:
inclusion criteria: * completion of any form of head and neck cancer treatment between 3 and 24 months previously at study enrollment * answer in the affirmative to at least one of two questions concerning dissatisfaction with the way their body looks or function * have clinically significant body image concerns as defined by (bis score \> 10) exclusion criteria: * undergoing head and neck cancer treatment at time of study enrollment * cognitive impairment that would preclude ability to provide informed consent * unable to read text on a computer screen * not able to read and understand english

Keywords: body image
bk virus post-kidney transplant: new practice versus traditional approach

Conditions: BK Virus Infection; BK Virus Nephropathy

Summary: the investigator's aim in this study is to evaluate the impact of a new standard of care protocol for the treatment of bk viremia and nephropathy (bkvan), which includes switching from tacrolimus to equivalent dose of cyclosporine in patients who have been diagnosed with bk viremia or bkvan based on their viral load, overall graft function (estimated glomerular filtration rate), acute rejection, and rate of graft loss due to rejection or bkvan.

this study will be a combined retrospective chart review and prospective observational study. this will be a single center project that will take place at loma linda university transplant institute. all adult kidney recipients who are determined to have bk viremia with a bk pcr viral load over 500 copy post-transplant and meet the inclusion criteria but no exclusion criteria will be enrolled and observed per study protocol. all kidney transplant recipients are routinely assessed for bk virus nephropathy and viremia post transplant as part of their standard care. patients with bk viremia or bk virus nephropathy will have adjustments in their immunosuppressive medication based on current guidelines and recommendations which include reduction in immunosuppression, treatment with medications with antiviral activity (cidofovir, ciprofloxacin, leflunomide, ivig) or switching from a tacrolimus (prograf)-based regimen to a cyclosporine-based regimen. retrospectively, the investigator will collect data on patients who have been diagnosed with bk viremia or bk virus nephropathy and have had such a management in past 66 months (from 1/1/2010 till 06/30/2015). prospectively, the investigator will enroll and collect data on patients who will be treated for bk viremia or bk virus nephropathy. as standard of care, all kidney transplant recipients will be seen routinely on weekly-biweekly basis in post-transplant clinic for up to 3 months then every 3 months for up to a year and yearly thereafter. all kidney transplant recipients will be monitored for bk viremia by having blood pcr tested on a monthly basis at 1, 2, 3, 6, and 12 months after transplant. also, all patients post-kidney transplant will be tested for bk viremia if there is an acute rise in their creatinine.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * recipient of kidney or combined kidney and pancreas * bk viremia confirmed with blood pcr test with viral load over 500 * bk virus nephropathy confirmed by kidney biopsy exclusion criteria: * recipient of combined organ transplant except kidney and pancreases * patient age \< 18 years * if patient does not consent for kidney biopsy * currently on treatment for acute rejection * patients with hiv, hep c or hep b infection * patients who are on other immunosuppression beside our standard regimen which includes prograf, cellcept / myfortic and prednisone

Keywords: kidney transplant bk viremia bk nephropathy
modifications in retinal microvascularization with targeted anti-angiogenic therapy in colorectal cancer

Conditions: Colorectal Cancer

Summary: retinal microvascularization can provide important informations to systemic vascular phenomena. the non-invasive quantitative description of the retinal vascularization is now possible by performing oct-angiography and their image analysis software (vascular density and retinal perfusion). systemic microvacular changes during the establishment of oncological treatment by targeted antiangiogenic therapy are little described in the literature. the objective of this pilot study is to describe the evolution of the retinal vascular density of patients with antiangiogenic drugs. in addition, the evolution of the retinal vascular density of patients on antiangiogenic drugs will study as a function of the response to the treatment and the toxicity of these treatments.

the main objective of this study is to describe the change in retinal vascular density of patients with first-line colorectal cancer treated with bevacizumab.

Eligibility criteria:
inclusion criteria: 1. patient over 18 years old starting first-line treatment for metastatic colorectal cancer including bevacizumab (avastin®) 2. systemic or intraocular anti-vegf treatment naïve 3. ecog ≤ 2 exclusion criteria: 1. pregnant woman, 2. minor patient or under legal protection 3. person deprived of liberty or under guardianship 4. inability to undergo medical monitoring of the trial 5. impossibility of carrying out the oct-a 6. patient with a contraindication to tropicamide 0.5% eye drops 7. patient with a history of degenerative macular pathology, vascular macular pathology or presenting an epiretinal membrane with traction phenomenon. 8. diabetes 9. patient for whom it is not possible to schedule an ophthalmology consultation before the start of treatment.

Keywords: retina oct-angiography anti-vegf microvascularization targeted therapy
delayed cord clamping in very low birth weight infants

Conditions: Very Low Birth Weight Infants; Premature Infants; Intraventricular Hemorrhage

Summary: the purpose of this study is to determine if there is a difference in neonatal outcomes with delayed umbilical cord clamping at 30 versus 60 seconds. our primary outcome will be intraventricular hemorrhage (ivh) (bleeding in the brain) in these infants.

immediately following delivery, up to 40% of the total blood volume available to the infant is in the placenta. over a period of 30 seconds to 3 minutes, a significant portion of this blood is transferred to the infant through the umbilical cord. delayed cord clamping following delivery facilitates this transfer of blood. preterm infants are very susceptible to the effects of anemia and hypovolemia. a recent meta-analysis showed that a brief delay in umbilical cord clamping (30-60 seconds) decreases the risk of anemia, blood transfusion, intraventricular hemorrhage, necrotizing enterocolitis, and the need for blood pressure support after delivery. the same meta-analysis showed no impact on apgar scores or hypothermia due to a brief delay in resuscitation efforts to allow delayed cord clamping. preterm infants are at significant risk for ivh and as high as 20% of very low birth weight infants will have it. ivh is an important cause of brain injury in these infants. in our study, we would like to determine the optimal timing of delayed cord clamping in order to prevent ivh in these infants.

Eligibility criteria:
inclusion criteria: * pregnant women who are expected to deliver a very low birth weight infant * neonates born weighing \>= 500g and \<1500 grams * mother 18 years of age or older * english speaking mother exclusion criteria: * placental abruption * vasa previa * fetal hydrops or other signs of fetal volume overload * other major fetal anomalies * placenta accreta * mother \< 18 years of age * non-english speaking mother * infants \>= 1500g (3.3 lbs) or \<500g

Keywords: delayed cord clamping
hydrolyzed collagen formulation vs placebo in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim of the study is to compare the 6 months clinical outcome of the treatment with a single intra-articular collagen injection versus a single placebo (saline solution) infiltration in the infiltrative treatment of knee osteoarthritis. the evaluation will be performed through clinical, subjective and objective assessments.

204 patients affected by knee osteoarthritis will be included in a double-blinded randomized controlled trial. patients in the experimental group will be treated with a single intra-articular injection of collagen (solution of low molecular weight peptides derived from hydrolyzed collagen) instead patients in the control arm, will be treated with a single intra-articular injection of placebo (saline solution). all patients will be evaluated by clinical examination before the infiltrative procedure and they will follow-up at 1,3,6 months. during the follow-up visits ,will be evaluated the inflammatory status of the knee by thermographic assessment and questionnaires, filled out by patients, will be utilized for clinical evaluations. after 6 months, patients in the control arm (saline solution injection), have the possibility to cross-over into the treatment arm (collagen) in which case they will be followed for an additional 6 months.

Eligibility criteria:
inclusion criteria: 1. unilateral involvement; 2. signs and symptoms of degenerative pathology of knee cartilage; 3. radiographic and mri signs of degenerative pathology of the knee cartilage (kellgren-lawrence 1-4 grades); 4. failure, defined as the persistence of symptoms, after at least one course of conservative treatment (pharmacological, physiotherapeutic or infiltrative treatment); 5. ability and consent of patients to actively participate in clinical follow-up; exclusion criteria: 1. patients who have undergone intra-articular injections of another substance in the previous 6 months; 2. patients undergoing knee surgery within the previous 12 months; 3. patients with malignant neoplasms; 4. patients with rheumatic diseases; 5. patients with diabetes; 6. patients with hematologic diseases (coagulopathies); 7. patients on anticoagulant therapy; 8. patients with metabolic disorders of the thyroid gland; 9. patients abusing alcoholic beverages, drugs or medications; 10. body mass index \> 35; 11. pregnant or lactating women. 12. patients with established hypersensitivity to bovine collagen or vitamin c. 13. patients with joint or peri-articular infections, emarto, erythema, or psoriatic patches in the knee joint area

Keywords: knee knee osteoarthritis collagen collagen injection osteoarthritis placebo randomized controlled trial double-blinded
the impact on linkage-to-care of an alternative hepatitis c screening method in pwid

Conditions: Hepatitis C; Drug Users; Harm Reduction; HIV

Summary: screening, diagnosis and treatment of hcv in pwid, should be part of a harm reduction strategy. treatment of hcv infected pwid should be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population. more frequent diagnosis, new methods that prevent loss of tracking, and access to antiviral treatment are all strategies that must be implemented jointly if the prevalence of hcv infection in our setting is to be reduced.


Eligibility criteria:
inclusion criteria: * pwid * \>18 years of age * signed consent form exclusion criteria:

Keywords: hepatitis c pwid linkage-to-care
clinical and molecular phenotyping in ibd

Conditions: IBD

Summary: inflammatory bowel disease (ibd) and psoriasis (ps) are common, chronic, immune- mediated barrier diseases with shared inflammatory pathways. current therapeutic interventions with anti-cytokine antibodies (tnf-α, il-23/il-12) reflect the intent to disrupt specific pathways of inflammatory immunopathology. individual responses to biological treatment can be thereby be exploited in a systems biology approach that employs a targeted mechanism of action (moa) to decipher molecular signatures of therapeutic responses in the context of a distinct disease entity. using a translational approach to investigate clinical and molecular phenotypes during therapeutic interference with cytokine signaling and leukocyte trafficking, the investigators aim to trace common and unique signatures of drug- and therapy-specific responses. patients will undergo endoscopic evaluation of the mucosal surface and gastrointestinal wall by conventional hd-colonoscopy, endoscopic ultrasound and confocal laser endomicroscopy prior to and during specific therapies with biologicals. in parallel, mucosa samples will be obtained to define molecular phenotypes during the course of therapy.


Eligibility criteria:
inclusion criteria: * inflammatory bowel disease * indication for biological therapy exclusion criteria: * pregnancy, breast feeding * no written informed consent to participate in the study

Keywords: vedolizumab infliximab
lletz under direct colposcopic vision

Conditions: Uterine Cervical Dysplasia

Summary: to assess the benefits of large loop excision of the transformation zone (lletz) under direct colposcopic vision.


Eligibility criteria:
inclusion criteria: * histologically proven cervical dysplasia * colposcopy prior to conization * informed consent exclusion criteria: * significant language barrier * a personal history of conization * pregnancy * the use of blood thinner * unwillingness to participate

Keywords: conization lletz loop excision randomized controlled trial colposcopy direct colposcopic vision intraoperative colposcopy